BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 23620238)

  • 1. Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation.
    Vignozzi L; Gacci M; Cellai I; Santi R; Corona G; Morelli A; Rastrelli G; Comeglio P; Sebastanelli A; Maneschi E; Nesi G; De Nunzio C; Tubaro A; Mannucci E; Carini M; Maggi M
    Prostate; 2013 Jun; 73(8):789-800. PubMed ID: 23620238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells.
    Vignozzi L; Cellai I; Santi R; Lombardelli L; Morelli A; Comeglio P; Filippi S; Logiodice F; Carini M; Nesi G; Gacci M; Piccinni MP; Adorini L; Maggi M
    J Endocrinol; 2012 Jul; 214(1):31-43. PubMed ID: 22562653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS.
    Vignozzi L; Gacci M; Cellai I; Morelli A; Maneschi E; Comeglio P; Santi R; Filippi S; Sebastianelli A; Nesi G; Serni S; Carini M; Maggi M
    Prostate; 2013 Sep; 73(13):1391-402. PubMed ID: 23765639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expressions of SIgA and alpha 1-AR in benign prostatic hyperplasia combined with chronic prostatitis and their implications].
    Gao WJ; Wang YM; Wang CH; Yang XK; Wan L; Li WP
    Zhonghua Nan Ke Xue; 2013 Apr; 19(4):315-20. PubMed ID: 23678709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic syndrome and lower urinary tract symptoms: the role of inflammation.
    Gacci M; Vignozzi L; Sebastianelli A; Salvi M; Giannessi C; De Nunzio C; Tubaro A; Corona G; Rastrelli G; Santi R; Nesi G; Serni S; Carini M; Maggi M
    Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):101-6. PubMed ID: 23165431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between lower urinary tract symptoms/benign prostatic hyperplasia and the number of components of metabolic syndrome.
    Park YW; Kim SB; Kwon H; Kang HC; Cho K; Lee KI; Kim YJ; Lee JH
    Urology; 2013 Sep; 82(3):674-9. PubMed ID: 23850334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical expression of interleukin-2 receptor and interleukin-6 in patients with prostate cancer and benign prostatic hyperplasia: association with asymptomatic inflammatory prostatitis NIH category IV.
    Engelhardt PF; Seklehner S; Brustmann H; Lusuardi L; Riedl CR
    Scand J Urol; 2015 Apr; 49(2):120-6. PubMed ID: 25363611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of MENT on primary cell cultures from benign prostatic hyperplasia and prostate carcinoma.
    Mendoza P; Sánchez C; Contreras HR; Vergara J; Acevedo C; Cabezas J; Huidobro C; Noé G; Castellón EA
    Int J Androl; 2009 Dec; 32(6):607-15. PubMed ID: 18637152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia.
    Penna G; Mondaini N; Amuchastegui S; Degli Innocenti S; Carini M; Giubilei G; Fibbi B; Colli E; Maggi M; Adorini L
    Eur Urol; 2007 Feb; 51(2):524-33; discussion 533. PubMed ID: 16905241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distribution of chronic prostatitis in radical prostatectomy specimens with up-regulation of bcl-2 in areas of inflammation.
    Gerstenbluth RE; Seftel AD; MacLennan GT; Rao RN; Corty EW; Ferguson K; Resnick MI
    J Urol; 2002 May; 167(5):2267-70. PubMed ID: 11956490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
    Hammarsten J; Högstedt B
    Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia.
    Rick FG; Schally AV; Block NL; Halmos G; Perez R; Fernandez JB; Vidaurre I; Szalontay L
    Prostate; 2011 May; 71(7):736-47. PubMed ID: 20945403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen concentrations and their receptors in the periurethral region are higher than those of the subcapsular zone in benign prostatic hyperplasia (BPH).
    Monti S; Di Silverio F; Toscano V; Martini C; Lanzara S; Varasano PA; Sciarra F
    J Androl; 1998; 19(4):428-33. PubMed ID: 9733145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of interleukin-8 in expressed prostatic secretion as a reliable biomarker of inflammation in benign prostatic hyperplasia.
    Liu L; Li Q; Han P; Li X; Zeng H; Zhu Y; Wei Q
    Urology; 2009 Aug; 74(2):340-4. PubMed ID: 19464042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia.
    Fibbi B; Penna G; Morelli A; Adorini L; Maggi M
    Int J Androl; 2010 Jun; 33(3):475-88. PubMed ID: 19508330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression of estrogen receptor beta in benign prostatic hyperplasia complicated by chronic prostatitis].
    Yang GQ; Li SW; Zheng H; Zhang WB; Hu WL; Zheng XM
    Zhonghua Nan Ke Xue; 2009 Apr; 15(4):314-7. PubMed ID: 19472903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of histological prostatitis in men with benign prostatic hyperplasia or adenocarcinoma of the prostate presenting without urinary retention.
    Edlin RS; Heyns CF; Van Vuuren SP; Zarrabi AD
    S Afr J Surg; 2012 Nov; 50(4):127-30. PubMed ID: 23217554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?
    Kramer G; Mitteregger D; Marberger M
    Eur Urol; 2007 May; 51(5):1202-16. PubMed ID: 17182170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormone concentration, metabolic disorders and immunoexpression of androgen and estrogen-alpha receptors in men with benign prostatic hyperplasia and testosterone deficiency syndrome.
    Ryl A; Rotter I; Slojewski M; Dolegowska B; Grabowska M; Baranowska-Bosiacka I; Laszczynska M
    Folia Histochem Cytobiol; 2015; 53(3):227-35. PubMed ID: 26400665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of histological prostatitis in patients with urinary retention and underlying benign prostatic hyperplasia or adenocarcinoma of the prostate.
    van Vuuren SP; Heyns CF; Zarrabi AD
    BJU Int; 2012 Apr; 109(8):1194-7. PubMed ID: 21851551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.